News
-
OINDP developer Nanopharm has announced the appointment of Mark Clement as non-executive Chairman of the Board. Clement has more than 25 years of experience in life sciences and is currently non-executive chairman or director of… Read more . . .
-
Orion Corporation has announced an agreement with Menarini Group to co-market its budesonide/formoterol Easyhaler DPI for the treatment of asthma and COPD in Germany, Italy, Spain, and Portugal. Each company will market the budesonide/formoterol inhaler… Read more . . .
-
GlaxoSmithKline Consumer Healthcare has announced the approval of Flonase Allergy Relief fluticasone propionate nasal spray for the treatment of allergic rhinitis for over-the-counter (OTC) sales in Canada. The nasal spray will be available OTC for… Read more . . .
-
Smartinhaler developer Adherium Limited has announced that Thomas Lynch has been appointed the company’s new Chairman and that Doug Wilson will step down from the board to take on the role of Medical Director on… Read more . . .
-
Particle characterization specialist Gateway Analytical will move to a new 17,000 sq ft (1,580 sq m) laboratory and office space in Gibsonia, Pennsylvania on September 1, 2016, according to an announcement by its parent company,… Read more . . .
-
According to Vectura, Mundipharma’s Phase 3 trial of the flutiform fluticasone/formoterol MDI failed to demonstrate statistically significant superiority compared to formoterol alone in reducing moderate and severe COPD exacerbations. Mundipharma had planned to seek approval… Read more . . .
-
Boehringer Ingelheim and Qualcomm Life have agreed to collaborate on development of a disposable wireless data sensor module for BI’s Respimat inhaler for COPD treatment. The sensor will connect with Qualcomm Life’s 2net platform. Qualcomm… Read more . . .
-
Daiichi Sankyo has announced that Japanese regulators have approved the use of its Inavir laninamivir octanoate hydrate DPI for the prevention of influenza in single doses of 20 mg for children under 10 years old… Read more . . .
-
Spyryx Biosciences, which is developing an inhaled peptide for the treatment of cystic fibrosis and other respiratory diseases, has announced the appointment of former Sunovion Head of Clinical Research Alistair Wheeler as Chief Medical Officer,… Read more . . .
-
Paradigm Biopharmaceuticals has announced the completion of a Phase 1 clinical trial of its Rhinosul pentosan polysulfate sodium (PPS) nasal spray for allergic rhinitis. Paradigm said that none of the 18 healthy volunteers involved in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.